Combination therapy with carboplatin and paclitaxel for small cell lung cancer

Lung cancer

“…Other symptoms commonly observed include worsening dyspnoea, weight loss, vocal changes and haemoptysis, however, a broad range of symptoms can present. As a result of the non-specific nature of many symptoms, patients are often diagnosed at an advanced stage of disease (Maori et al, 2019).…”

“…Diagnosis is made by identifying a low serum sodium level with decreased osmolality and a high urine sodium level with no signs of organ failure or other cause of hyponatraemia. Patients presenting with this should be referred for management in secondary care with close attention to fluid balance (Maori et al, 2019).…”

“…There may be a role for radiotherapy, particularly cranial irradiation, which can alleviate symptoms associated with brain metastases such as headache or seizures. As a GP it is important to explain to patients the potential side effects and challenges of radiotherapy, including fatigue and weight loss (Maori et al, 2019).…”

“…Recent developments have included the development of immunotherapies for small cell cancer including nivolumab and atezolizumab, which have been shown to improve survival rates in certain patient groups. Patients must still be monitored closely for signs of a relapse, and in this event an aggressive combination of four chemotherapy medications may be used (Maori et al, 2019). The treatment options continue to evolve and liaising with colleagues in secondary care remains essential.…”

Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience

“…Without a standard plan for third-line and subsequent-line treatment, SCLC has a weak overall curative effect and a 5-year survival rate estimated to only 7%. 2 Paclitaxel is an antitumor drug with a definite effect on a variety of malignant tumors which reduces microtubule generation. It is a component of the standard regimen of non-SCLC.…”